Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 20, 2025
A Safe Haven for Newborns Reunites Firefighters with Baby Hope 21 Years Later
EIN Presswire
·
March 20, 2025
A Different Type of Family Reunion MIAMI, FL, UNITED STATES, March 20, 2025 /EINPresswire.com/ -- The Gloria M. Silverio Foundation, 501 C3, d/b/a A Safe Haven for Newborns, was founded 24 years ago by Nick Silverio with the sole mission of ending …
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
GlobeNewswire
·
March 20, 2025
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer …
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
GlobeNewswire
·
March 20, 2025
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million upon achieving near-term milestones Non-dilutive …
GENFIT annonce le closing du royalty financing avec HCRx et les résultats de l’Offre de Rachat aux porteurs d’OCEANEs 2025
GlobeNewswire
·
March 20, 2025
GENFIT a finalisé la mise en œuvre d’un royalty financing avec HCRx d’un montant maximum de 185 millions d'euros à la suite de l'approbation unanime des obligataires des OCEANEs 2025. Ce closing a déclenché un premier versement de 130 millions d'euros, …
YourUpdate TV Speaks with Mia Syn About National Nutrition Month
GlobeNewswire
·
March 20, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- March is National Nutrition Month, a time to focus on making informed choices about food, supplements, and nutrition to develop healthy habits. Registered dietitian and nationally recognized nutrition expert, …
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
GlobeNewswire
·
March 20, 2025
MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced …
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
GlobeNewswire
·
March 20, 2025
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel …
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
GlobeNewswire
·
March 20, 2025
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has …
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GlobeNewswire
·
March 20, 2025
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee …
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
GlobeNewswire
·
March 20, 2025
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context …
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
GlobeNewswire
·
March 20, 2025
Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be …
NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
GlobeNewswire
·
March 20, 2025
Des données évaluant la sécurité et les premiers signes d’efficacité, y compris la mise à jour de la survie sans progression (SSP) locale, issues de la partie escalade de dose achevée d’une étude de Phase 1 sur la ré-irradiation avec JNJ-1900 (NBTXR3) chez …
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
GlobeNewswire
·
March 20, 2025
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused …
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewswire
·
March 20, 2025
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million …
Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information
GlobeNewswire
·
March 20, 2025
WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the fourth quarter …
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
GlobeNewswire
·
March 20, 2025
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and …
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 20, 2025
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and …
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 20, 2025
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron …
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
GlobeNewswire
·
March 20, 2025
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data …
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 20, 2025
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Positive Overall …